| NICE Cancer Service Guideline |
Improving outcomes in urological cancers CSG2 |
| NICE Diagnostics Guidance |
MRI fusion biopsy systems for diagnosing prostate cancer DG53 |
| NICE Diagnostics Guidance |
Transperineal biopsy for diagnosing prostate cancer DG54 |
| NICE Guideline |
Bladder cancer: diagnosis and management NG2 |
| NICE Guideline |
Prostate cancer: diagnosis and management NG131 |
| NICE Interventional Procedures Guidance |
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer IPG752 |
| NICE Interventional Procedures Guidance |
Cryotherapy for recurrent prostate cancer IPG119 |
| NICE Interventional Procedures Guidance |
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer IPG638 |
| NICE Interventional Procedures Guidance |
Focal therapy using cryoablation for localised prostate cancer IPG423 |
| NICE Interventional Procedures Guidance |
Focal therapy using high-intensity focused ultrasound for localised prostate cancer IPG424 |
| NICE Interventional Procedures Guidance |
High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer IPG174 |
| NICE Interventional Procedures Guidance |
High-intensity focused ultrasound for prostate cancer IPG118 |
| NICE Interventional Procedures Guidance |
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer IPG628 |
| NICE Interventional Procedures Guidance |
Irreversible electroporation for treating prostate cancer IPG572 |
| NICE Interventional Procedures Guidance |
Irreversible electroporation for treating prostate cancer IPG768 |
| NICE Interventional Procedures Guidance |
Laparoscopic retroperitoneal lymph node dissection for testicular cancer IPG158 |
| NICE Interventional Procedures Guidance |
Low dose rate brachytherapy for localised prostate cancer IPG132 |
| NICE Interventional Procedures Guidance |
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer IPG656 |
| NICE Medical Technologies Guidance |
Synergo for non-muscle-invasive bladder cancer MTG61 |
| NICE Technology Appraisal |
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) TA797 |
| NICE Technology Appraisal |
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) TA674 |
| NICE Technology Appraisal Guidance |
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen TA259 |
| NICE Technology Appraisal Guidance |
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated TA387 |
| NICE Technology Appraisal Guidance |
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer TA721 |
| NICE Technology Appraisal Guidance |
Apalutmide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 |
| NICE Technology Appraisal Guidance |
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA741 |
| NICE Technology Appraisal Guidance |
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable TA739 |
| NICE Technology Appraisal Guidance |
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy TA788 |
| NICE Technology Appraisal Guidance |
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel TA391 |
| NICE Technology Appraisal Guidance |
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer TA903 |
| NICE Technology Appraisal Guidance |
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer TA660 |
| NICE Technology Appraisal Guidance |
Degarelix for treating advanced hormone-dependent prostate cancer TA404 |
| NICE Technology Appraisal Guidance |
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer TA101 |
| NICE Technology Appraisal Guidance |
Enzalutamide for hormone-relapsed non-metastatic prostate cancer TA580 |
| NICE Technology Appraisal Guidance |
Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen TA316 |
| NICE Technology Appraisal Guidance |
Enzalutamide for treating hormone-sensitive metastatic prostate cancer TA712 |
| NICE Technology Appraisal Guidance |
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated TA377 |
| NICE Technology Appraisal Guidance |
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence TA817 |
| NICE Technology Appraisal Guidance |
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy TA530 |
| NICE Technology Appraisal Guidance |
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer TA831 |
| NICE Technology Appraisal Guidance |
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer TA887 |
| NICE Technology Appraisal Guidance |
Padeliporfin for untreated localised prostate cancer TA546 |
| NICE Technology Appraisal Guidance |
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases TA412 |
